Ron MacFarland

726 total citations
10 papers, 573 citations indexed

About

Ron MacFarland is a scholar working on Oncology, Hematology and Virology. According to data from OpenAlex, Ron MacFarland has authored 10 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Hematology and 4 papers in Virology. Recurrent topics in Ron MacFarland's work include Hematopoietic Stem Cell Transplantation (5 papers), HIV Research and Treatment (4 papers) and Chemokine receptors and signaling (4 papers). Ron MacFarland is often cited by papers focused on Hematopoietic Stem Cell Transplantation (5 papers), HIV Research and Treatment (4 papers) and Chemokine receptors and signaling (4 papers). Ron MacFarland collaborates with scholars based in United States, Canada and United Kingdom. Ron MacFarland's co-authors include Gary Calandra, Gary Bridger, Karin Badel, Gary Calandra, Douglas A. Stewart, Clayton A. Smith, Amanda F. Cashen, John F. DiPersio, Stephen Becker and Feng Gao and has published in prestigious journals such as Blood, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Ron MacFarland

10 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron MacFarland United States 9 301 287 252 126 79 10 573
Barbara Ferstl Germany 10 112 0.4× 150 0.5× 92 0.4× 105 0.8× 68 0.9× 13 316
Francis Relouzat France 9 216 0.7× 308 1.1× 550 2.2× 187 1.5× 26 0.3× 20 910
Sherly Mosessian United States 8 144 0.5× 84 0.3× 75 0.3× 423 3.4× 68 0.9× 12 627
V. Granger United Kingdom 11 67 0.2× 195 0.7× 162 0.6× 136 1.1× 82 1.0× 15 467
Monica Jones United States 13 274 0.9× 181 0.6× 533 2.1× 52 0.4× 25 0.3× 21 654
F Le Deist France 16 96 0.3× 95 0.3× 411 1.6× 123 1.0× 25 0.3× 28 607
Sabina Pierpaoli Italy 12 76 0.3× 188 0.7× 166 0.7× 230 1.8× 40 0.5× 14 505
M H Holguin United States 8 87 0.3× 238 0.8× 481 1.9× 201 1.6× 13 0.2× 10 715
K Yasukawa Japan 4 198 0.7× 53 0.2× 264 1.0× 102 0.8× 13 0.2× 6 488
Steven Stein United States 8 128 0.4× 87 0.3× 191 0.8× 56 0.4× 9 0.1× 11 395

Countries citing papers authored by Ron MacFarland

Since Specialization
Citations

This map shows the geographic impact of Ron MacFarland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron MacFarland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron MacFarland more than expected).

Fields of papers citing papers by Ron MacFarland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron MacFarland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron MacFarland. The network helps show where Ron MacFarland may publish in the future.

Co-authorship network of co-authors of Ron MacFarland

This figure shows the co-authorship network connecting the top 25 collaborators of Ron MacFarland. A scholar is included among the top collaborators of Ron MacFarland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron MacFarland. Ron MacFarland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Moyle, Graeme, Edwin DeJesus, Marta Boffito, et al.. (2009). Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1. Clinical Infectious Diseases. 48(6). 798–805. 60 indexed citations
2.
Stewart, Douglas A., Clayton A. Smith, Ron MacFarland, & Gary Calandra. (2009). Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Biology of Blood and Marrow Transplantation. 15(1). 39–46. 72 indexed citations
3.
Bodart, V., Marilyn C. Darkes, Jean Labrecque, et al.. (2009). Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochemical Pharmacology. 78(8). 993–1000. 48 indexed citations
4.
Nyunt, Myaing M., Stephen Becker, Ron MacFarland, et al.. (2008). Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(5). 559–565. 19 indexed citations
5.
Cashen, Amanda F., Feng Gao, Gary Calandra, et al.. (2008). A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 14(11). 1253–1261. 107 indexed citations
6.
Flexner, Charles, Shelia B. Dunaway, Jeong‐Gun Park, et al.. (2008). Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 52(5). 1630–1634. 18 indexed citations
7.
Stone, Nimalie D., Shelia B. Dunaway, Charles Flexner, et al.. (2007). Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects. Antimicrobial Agents and Chemotherapy. 51(7). 2351–2358. 103 indexed citations
8.
9.
Burroughs, Lauri, Marco Mielcarek, Marie-Térèse Little, et al.. (2005). Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood. 106(12). 4002–4008. 63 indexed citations
10.
Hübel, Kai, W. Conrad Liles, Hal E. Broxmeyer, et al.. (2004). Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. PubMed. 1(3). 165–172. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Ferstl Breakdown of academic impact, for papers by Francis Relouzat Breakdown of academic impact, for papers by Sherly Mosessian Breakdown of academic impact, for papers by V. Granger Breakdown of academic impact, for papers by Monica Jones Breakdown of academic impact, for papers by F Le Deist Breakdown of academic impact, for papers by Sabina Pierpaoli Breakdown of academic impact, for papers by M H Holguin Breakdown of academic impact, for papers by K Yasukawa Breakdown of academic impact, for papers by Steven Stein
Rankless by CCL
2026